BJMO - volume 13, issue 8, december 2019
G. El Hachem MD, J. Kerger MD, PhD
After last year’s ESMO meeting in Munich, the recent ESMO Congress in Barcelona again proved to be a ‘grand cru’ in gynaecological cancer, with the confirmation of the role of maintenance therapy with PARP inhibitors in first-line therapy of advanced ovarian cancer, even beyond BRCA mutation. Additionally, recent progress in the management of endometrial and cervical cancer will be highlighted in this overview.
Read moreBJMO - volume 13, issue 3, may 2019
G. El Hachem MD, Y. Jounblat MD, A. Awada MD, PhD, A. Gombos MD
Triple-negative breast cancer is a heterogeneous subtype of breast carcinoma lacking the expression of oestrogen, progesterone and human epidermal growth factor 2 receptors. For many decades, cytotoxic chemotherapy has been the standard of care offering only a short-living disease control. Knowing its poor outcome and aggressive behaviour, researchers are trying to find new therapeutic options hoping to improve the survival of this population. Many cytotoxic and targeted therapies were tested without major benefit. However, in the era of molecular and mutational classification of tumours, as well as the immune mediated mechanisms of proliferation and progression, the trials are currently oriented towards the identification of potential targets in the tumoral heterogenic environment. Here, we present a review of literature concerning the potential anti-neoplastic options and novel therapies for metastatic triple-negative breast cancers: new cytotoxic agents, new targeted therapies, anti-angiogenic agents, antibody-drug conjugates, poly-ADP ribose transferase inhibitors and immunotherapy. Many agents are promising, yet not powerful enough to get approvals for use into clinical practice.
(BELG J MED ONCOL 2019;13(3):84–92)
Read moreBJMO - 12, issue 3, february 2018
X. Wang , G. El Hachem MD, W. Bekolo , L. Dal Lago , A. Georgala MD, T. Pepersack , S. Aspeslagh MD, PhD, L. Buisseret MD, T. Gil MD, A. Awada MD, PhD
BJMO - 12, issue 3, february 2018
G. El Hachem MD, C. Jungels MD
BJMO - 12, issue 3, february 2018
G. El Hachem MD, L. Polastro , J. Kerger MD, PhD
BJMO - 12, issue 3, february 2018
Y. Jounblat MD, G. El Hachem MD, A. Drowart , J. Kerger MD, PhD
BJMO - volume 11, issue 7, november 2017
G. El Hachem MD, J. Kerger MD, PhD
With more than 24,000 attendees, ESMO 2017 was the biggest oncology meeting ever organised in Europe. In the gynaecological cancer domain, there were some potentially practice-changing presentations in ovarian and cervical cancer, whereas new data in endometrial cancer were very sparse.
(BELG J ONCOL 2017;11(7):301–308)
Read more
Top
